CRN04777
Hyperinsulinism
Phase 1Completed (Phase 2 planned)
Key Facts
Indication
Hyperinsulinism
Phase
Phase 1
Status
Completed (Phase 2 planned)
Company
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is building a premier, endocrine-rooted global pharmaceutical company dedicated to improving the lives of patients with endocrine disorders. Founded by scientists with a proven track record in GPCR drug discovery, the company has advanced a pipeline of novel, oral nonpeptide therapies targeting significant unmet needs. With a lead program in Phase 3 for acromegaly and a growing pipeline, Crinetics is positioned to become a leader in next-generation endocrine care.
View full company profile